Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for rituximab biosimilar Ruxience

Ruxience will be available as 100 mg and 500 mg concentrates for solution for infusion. Data show that Ruxience has comparable quality, safety and efficacy to MabThera (rituximab).

Source:

European Medicines Agency